Advances in the Pharmacological Management of Parkinson's Disease

BackgroundParkinson's disease (PD) is a complex, progressive neurodegenerative disorder with patients experiencing an increased number and severity of motor and non-motor symptoms over the course of their disease. Despite the exponentially increasing prevalence of PD worldwide, therapies for people with PD remain symptomatic in nature.Purpose of ReviewThis review provides an update on the advances in the pharmacological management of both motor and non-motor symptoms in people with PD.Recent FindingsIt highlights several newly approved pharmacological options for ON/OFF motor fluctuations and levodopa-induced dyskinesia. This review details the novel device-aided therapies of intravenous levodopa/ carbidopa along with the unique delivery systems approved for PD rescue therapy. This review concludes with an update on the recent progress made in the treatment of a number of non-motor symptoms.ConclusionAlthough disease-modifying and neurorestorative therapies remain the Holy Grail in PD, the current advances in symptomatic pharmacological therapies are welcomed in the armamentarium of PD care.